The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group

Franzese, Ciro; Marvaso, Giulia; Borghetti, Paolo; Trodella, L.; Sepulcri, Matteo; Matrone, Fabio; Nicosia, Luca; Timon, G.; Ognibene, Lucia; Vinciguerra, A.; Alongi, Filippo; Bortolus, Roberto; Corti, L.; Ramella, Sara; Magrini, Stefano Maria; Livi, Lorenzo; Jereczek‐Fossa, Barbara Alicja; Scorsetti, Marta; Arcangeli, Stefano

doi:10.1007/s10585-021-10131-w

Cited by 20 publications

(22 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Traditionally, SBRT has been employed in oligoprogressive and oligometastatic patients. The aim of this strategy was double: firstly, to achieve better LC of the irradiated lesion and secondly, to improve PFS in oligometastatic patients and delay the change to a different line of systemic therapy by eliminating resistant tumor subclones in oligoprogressive patients 44–52 . However, most of the evidence on this combination is based on retrospective studies, and clinical trials are limited to early phase, nonrandomized studies with small sample sizes (Table 3).…”

Section: Resultsmentioning

confidence: 99%

Stereotactic body radiation therapy for kidney cancer. Where do we stand?

et al. 2023

View full text Add to dashboard Cite

AbbreviationsBED = biologically effective dose CN = cytoreductive nephrectomy CSS = cancer-specific survival EORTC = European Organization for Research and Treatment of Cancer ESTRO = European Society for Radiotherapy and Oncology fx = fraction GFR = glomerular filtration rate ICI = immune checkpoint inhibitor IrAE = immune-related adverse effect LC = local control LRC = localized renal cancer ORR = objective response rate OS = overall survival PFS = progression-free survival RT = fractionated radiotherapy SABR = stereotactic ablative body radiotherapy SBRT = stereotactic body radiation therapy TKI = tyrosine-kinase inhibitor

show abstract

Section: Resultsmentioning

confidence: 99%

Stereotactic body radiation therapy for kidney cancer. Where do we stand?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Although predictors of longer PFS remain unclear, patients with an indolent disease course (longer duration of systemic therapy before progression [42] and fewer metastases [five or fewer] at oligoprogression [41]) may benefit most from SABR in the oligoprogressive setting. Franzese et al [43] also suggested that outcomes after SABR are strongly correlated with the volume of the metastatic burden. While a cutoff was not established in their retrospective study, a higher total number of metastases was the only predictor of worse LC, PFS, and OS.…”

Section: Sabr In the Oligoprogressive Settingmentioning

confidence: 99%

The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Guévelou

Sargos

Ploussard

et al. 2023

European Urology Focus

View full text Add to dashboard Cite

“…Median PFS and OS times were 11.3 and 29.7 months, respectively. In the largest retrospective study to date, Franzese et al [26 ▪ ] analyzed 207 mRCC (oligorecurrent or oligoprogressive) patients who underwent SRT at different Italian centers. Of the total, 78 (31.8%) received concomitant systemic therapy utilizing various agents (including TKI or ICI).…”

Section: Stereotactic Radiotherapymentioning

confidence: 99%

“…Median PFS and OS times were 11.3 and 29.7 months, respectively. In the largest retrospective study to date, Franzese et al[26…”

mentioning

confidence: 99%

Metastasis-directed treatment in kidney cancer

Jackson

Franco

Wang

et al. 2023

Current Opinion in Urology

View full text Add to dashboard Cite

Purpose of review To provide a critical overview of the latest evidence on the role of metastasis-direct treatment (MDT) in the management of metastatic renal cell carcinoma (mRCC). Recent findings This is a nonsystematic review of the English language literature published since January 2021. A PubMed/MEDLINE search using various search terms was conducted, including only original studies. After title and abstract screening, selected articles were grouped into two main areas which mirror the main treatment options in this setting: surgical metastasectomy (MS) and stereotactic radiotherapy (SRT). While a limited number of retrospective studies have been reported on surgical MS, the consensus of these reports is that extirpation of metastasis should be part of a multimodal management strategy for carefully selected cases. In contrast, there have been both retrospective studies and a small number of prospective studies on the use of SRT of metastatic sites. Summary As the management of mRCC rapidly evolves, and evidence on MDT – both in the form of MS and SRT – has continued to build over the past 2 years. Overall, there is growing interest in this therapeutic option, which is increasingly being implemented and seems to be safe and potentially beneficial in well selected disease scenarios.

show abstract

The role of stereotactic body radiation therapy and its integration with systemic therapies in metastatic kidney cancer: a multicenter study on behalf of the AIRO (Italian Association of Radiotherapy and Clinical Oncology) genitourinary study group

Cited by 20 publications

References 31 publications

Stereotactic body radiation therapy for kidney cancer. Where do we stand?

Stereotactic body radiation therapy for kidney cancer. Where do we stand?

The Emerging Role of Extracranial Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma: A Systematic Review

Metastasis-directed treatment in kidney cancer

Contact Info

Product

Resources

About